Bologna, Italy – 15 October 2025. The Dioptra Project, a Horizon Europe initiative revolutionising colorectal cancer screening through AI-driven, personalised methodologies, will hold its next consortium meeting in Bologna on 22–23 October 2025. The event will be hosted by i2Grow, Innovation to Grow, and proudly sponsored by the Emilia-Romagna Region, recognised as a European leader in innovation and technological excellence.
The meeting will bring together over 50 researchers, clinicians, technologists, and policy experts from across Europe to review progress and align on future strategies for implementing Dioptra’s holistic screening protocol. This protocol integrates novel biomarkers, behavioural data, and AI-powered decision support systems to enhance the early detection and prevention of colorectal cancer.
Regione Emilia-Romagna: A Beacon of Innovation
Sponsorship by Regione Emilia-Romagna underscores its pivotal role in fostering cutting-edge research and driving digital transformation. As Italy’s top-ranked region for innovation, according to the European Innovation Scoreboard, Emilia-Romagna continues to invest in high-impact initiatives that bridge science, industry, and public health.
A key example of this commitment is the recent launch of DAMA – Data Manufacturing Technopole, located in Bologna. DAMA is a world-class hub for supercomputing, big data, and artificial intelligence, hosting the Leonardo supercomputer, the European Centre for Medium-Range Weather Forecasts (ECMWF), and soon, advanced quantum computing systems. DAMA exemplifies the region’s vision of integrating data science with industrial innovation to address global challenges —including climate change and healthcare.
About DIOPTRA
DIOPTRA, a 4-year Horizon Europe Research and Innovation Action, is powered by a powerful consortium of 28 partners from 15 countries: Institute of Communication and Computer Systems (Greece – Coordinator), Martel GmbH (Switzerland), Tecreando BV (Netherlands), Sphynx Technology Solutions (Switzerland), Panepistimio Ioanninon - University of Ioannina (Greece), Smartsol SIA (Latvia), I2Grow Innovation to Grow SRL (Italy), Netcompany-Intrasoft SA (Luxembourg), Protavio Ltd (Greece), Computer Solutions Cyprus LTD (Cyprus), Dubrava University Hospital (Croatia), Arthur’s Legal BV (Netherlands), CSI Center For Social Innovation LTD (Cyprus), Centre Hospitalier Universitaire De Liege (Belgium), UAB Teraglobus (Lithuania), Vilabs LTD (Cyprus), Randers Regional Hospital, Central Denmark Region (Denmark), Univerzitetni Klinicni Center Maribor (Slovenia), Komiteen For Sundhedsoplysning (Denmark), Federation Europeenne des Hopitaux et des Soins de Sante (Belgium), D.Tsakalidis-G.Domalis OE (Greece), Ainigma Technologies (Belgium), Fundación Burgos por la Investigación de la Salud (Spain), Hepatogastroenterology Unit, Second Department of Internal Medicine – Propaedeutic, Medical School, National and Kapodistrian University of Athens, ‘‘Attikon” University General Hospital, Athens (Greece), Cambridge Medical Academy (United Kingdom), Linac-Pet Scan Opco Limited – German Oncology Center (Cyprus), Geniko Antikarkiniko Ogkologiko Nosokomeio Athinon O Agios Savvas (Greece), Biobank Graz of the Medical University of Graz (Austria). Each DIOPTRA partners carry the background knowledge and have documented expertise on all necessary fields.
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.This work has received funding from the Swiss State Secretariat for Education, Research and Innovation (SERI).Funded by UK Research and Innovation (UKRI) under the UK government’s Horizon Europe funding guarantee [grant number 10056682].
